PDF
(Download)
|
- Olive (Olea europaea) Leaf
- Menopause
- Antioxidants
|
Date:
06-30-2014 | HC# 021466-499
|
Re: Pharmacokinetics of Olive Leaf Bioactives
García-Villalba
R, Larrosa M, Possemiers S, Tomás-Barberán FA, Espín JC. Bioavailability of
phenolics from an oleuropein-rich olive (Olea
europaea) leaf extract and its acute effect on plasma antioxidant status:
comparison between pre- and postmenopausal women. Eur J Nutr. June 2014;53(4):1015-1027.
Olive
(Olea europaea) leaves contain the
bioactive phenolic compounds oleuropein and hydroxytyrosol, shown to be
bioactive in treating chronic diseases in clinical, in vivo, and in vitro
studies. Oleuropein and hydroxytyrosol are reported to alleviate bone loss in
in vivo and in vitro models of osteoporosis. As excess reactive oxygen species
has been correlated with bone loss in postmenopausal women, this clinical,
observational study addressed whether an oleuropein-rich olive leaf extract
would impact antioxidant activity in pre- and postmenopausal women. The
pharmacokinetics and urine excretion of phenolics in these subjects was also
investigated.
Subjects
were recruited through the Drug Research Unit of Maastricht, Maastricht,
Netherlands, and were 18-75 years old. Women were subject to a physical exam
including vital signs, height, weight, and blood collection for laboratory
parameters. If the women were premenopausal, they underwent a pregnancy test,
and those with prior hormone problems and permanent hormone modifications were
excluded. Included premenopausal women were required to use oral contraception,
and the study could not occur on the first 3 days of its usage.
Included
postmenopausal women were required to have been in menopause for at least 2
years. Women were not permitted to consume hormones, "medicinal
products," food supplements, anti-osteoporosis medication, or vitamins. Subjects
were excluded if they smoked, had liver function problems, "abnormal"
serum creatinine, body mass index (BMI) either < 18 or > 30 kg/m2,
were using medications, supplements, or had donated blood in the 4 weeks prior
to the study. In total, 8 each of pre- and postmenopausal women participated.
The
premenopausal women were 19-25 years old with an average BMI of 22.7 kg/m2,
and postmenopausal women, 51-66 years old, had an average BMI of 23.8 kg/m2.
Baseline physical parameters were normal for all women. After fasting (except
for water) from midnight, subjects arrived at the clinic the morning of the
study day, and blood was collected within 2 hours of ingesting olive leaf
extract (250 mg capsules taken with water in 1 minute). The source of the plant
material was not provided. Blood was taken at 30 minutes, 1, 2, 3, 4, 6, 8, 12,
and 24 hours. Urine was also taken and combined into 0-4, 4-8, 8-12, 12-16, and
16-24 hour samples. Subjects were fed at 2, 4, 9, and 13 hours, and had vital
signs measured and any adverse side effects recorded at the end of the day.
High-performance
liquid chromatography (HPLC), both alone and coupled to mass spectrometry, was used
to detect and quantify phenolics in both the olive leaf extract and in plasma
and urine samples. To assess antioxidant activity, the ferric reducing
antioxidant power (FRAP) assay was used and malondialdehyde (MDA, an indicator
of lipid peroxidation) concentrations were determined.
No
adverse side effects were noted during the study, and all subjects completed
the protocol. In plant material, oleuropein was the most abundant compound detected,
with hydroxytyrosol found at smaller concentrations. Metabolites found in
plasma and urine consisted of methylated, sulfated, or glucuronidated compounds
of olive leaf phenolics and other compounds. None of the parent or metabolite
compounds were found in plasma or urine at baseline. Compounds showed
comparable absorption patterns in both pre- and postmenopausal women, with
hydroxytyrosol glucuronide arriving at maximum peak concentration (Cmax)
first and hydroxytyrosol sulfate last, and all metabolites reaching Cmax
within the first 35-75 minutes. All metabolites found in the serum were also
detected in the urine.
The
Cmax of hydroxytyrosol glucuronide, hydroxytyrosol sulfate,
oleuropein aglycon glucuronide, and an oleuropein aglycon derivative were
significantly more elevated in postmenopausal women than premenopausal women
(P<0.05). Additionally, the excretion of hydroxytyrosol sulfate and
hydroxytyrosol sulfoglucuronide was significantly higher in premenopausal women
than postmenopausal women (P<0.05). In plasma, there was a significant
positive correlation with the area under the curve from beginning timepoint to
ending timepoint (AUCall) of hydroxytyrosol glucuronide and oleuropein aglycon
glucuronide (P<0.05), and hydroxytyrosol sulfate and oleuropein aglycon
glucuronide (P<0.05). In urine, there was a significant positive correlation
with hydroxytyrosol glucuronide AUCall and that of hydroxytyrosol
sulfoglucuronide (P=0.03), homovanillic alcohol glucuronide (P<0.05),
oleuropein aglycon glucuronide (P=0.04), and an oleuropein aglycon derivative (P=0.01).
In
urine, the total amount recovered, AUCall, and AUC∞ (final measured
concentration divided by elimination rate constant) of hydroxytyrosol
sulfoglucuronide were significantly positively correlated with this compound's
plasma AUCall, AUC∞, and Cmax (P<0.05). These statistical
relationships were observed when analyses were done of all women and pre- and
postmenopausal women separately. Plasma FRAP activity and MDA concentrations
were not different between pre- and postmenopausal women at baseline. At 30
minutes after ingestion of the olive leaf extract, postmenopausal women had
significantly less MDA than premenopausal women (P=0.016).
In
summary, this study reports the detection of hydroxytyrosol glucuronide and
hydroxytyrosol sulfoglucuronide in plasma, which is somewhat contradictory with
other studies. It is mentioned that the correlations among compounds in plasma
may reflect compound modifications in the gastrointestinal tract. Additionally,
hormonal changes may be one factor among others in the significantly different
amounts of compounds seen in premenopausal compared to postmenopausal women. The
lesser amount of MDA in postmenopausal women 30 minutes after consumption of
oleuropein-rich olive leaf extract may suggest its use in alleviating oxidative
damage; however, the bioactivity of these compounds and metabolites in chronic
disease needs further investigation.
—Amy C. Keller,
PhD
|